Drug Information: Galiximab is a chimeric human-macaque anti-CD80 monoclonal antibody which targets B-cells, including malignant cells. Blocking this site with antibodies appears to produce a range of anti-cancer effects. It is taken intravenously, weekly for four weeks.
Side Effects: Lymphopenia (44%), Leucopenia (38%), fatigue, (38%), neutropenia (23%), chills (23%)
Trial Information: A trial of galiximab in 37 relapsed and refractory follicular lymphoma patients showed a response rate of just 11%, although this included 2 complete remissions.
Galiximab showed some promise when used in combination with rituximab. One trial in relapsed patients (40% of whom were previously treated with rituximab) showed a response rate of 66%, including 19% achieving complete remission. On the other hand, results presented in ASH 2010 on a similar population showed the response rate for rituximab + galiximab (51%) was only slightly higher than rituximab and a placebo (48%). However, those patients who received the combination regimen had their risk of death within a year reduced by 26%.
Currently there is little research activity with respect to galiximab, and no trials are recruiting patients as of January 2011.
Published Studies
Isabelle Bence-Bruckler et al. "A Phase II, Double-Blind Placebo-Controlled Trial of Rituximab + Galiximab." ASH Annual Meeting (December 2010).
J.P. Leonard et al. "A Phase I/II Study of Galiximab." Annals of Oncology (2009).
Myron S. Czuczman et al. "Phase I/II Study of Galiximab." Journal of Clinical Oncology (2005).
No comments:
Post a Comment